粪卟啉I作为内源性生物标志物检测慢性肾病中OATP1B活性降低及消除途径转变
本研究通过扩展生理药代动力学模型,探究慢性肾病患者粪卟啉I基线升高的机制。模型纳入血浆游离分数、OATP1B介导的肝摄取清除率、肾清除率和内源性合成等协变量,成功重现患者基线升高及利福平介导的AUC比值变化。结果表明慢性肾病相关OATP1B功能下降,监测粪卟啉I可检测OATP1B底物在慢性肾病患者中的药物相互作用风险。
要点
- 慢性肾病患者的粪卟啉I基线升高与OATP1B活性降低及消除途径转变有关。
- 重度慢性肾病中肾消除几乎完全下降,增加粪卟啉I经OATP1B转运的比例。
- 监测粪卟啉I有助于发现慢性肾病患者中OATP1B药物的相互作用风险。
核心结论
- 机制建模支持慢性肾病相关OATP1B功能降低,为OATP1B介导的药物相互作用前瞻性PBPK建模提供依据。
- 监测粪卟啉I可检测慢性肾病患者中OATP1B药物的相互作用风险,该风险可能被基于健康受试者匹伐他汀数据的推断低估。
研究设计与样本
- 研究采用生理药代动力学(PBPK)模型,将既往开发的模型扩展至慢性肾病患者群体。
- 以粪卟啉I为对象,逐步评估慢性肾病相关协变量对血浆游离分数、OATP1B介导的肝摄取清除率、肾清除率和内源性合成的影响。
主要发现
- 模型通过纳入以下疾病相关变化成功重现慢性肾病患者粪卟啉I基线升高及利福平介导的AUC比值升高:血浆游离分数增加13%,轻度和中重度慢性肾病中OATP1B介导的肝摄取清除率分别降低29%和39%,肾清除率下降与肾小球滤过率下降成比例,重度慢性肾病中内源性合成降低27%。
- 重度慢性肾病中粪卟啉I肾消除几乎完全下降,增加其经OATP1B转运的比例,解释了健康受试者与慢性肾病患者之间粪卟啉I-利福平相互作用的差异。
临床怎么用
- 临床可监测粪卟啉I以评估慢性肾病患者OATP1B活性降低及药物相互作用风险。
- 对于经肝和肾双途径消除的OATP1B底物药物,在慢性肾病患者中应警惕基于健康受试者匹伐他汀数据外推可能低估的相互作用风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coproporphyrin I (CPI) is an endogenous biomarker of organic anion transporting polypeptide 1B transporter (OATP1B). CPI plasma baseline was reported to increase with severity of chronic kidney disease (CKD). Further, ratio of CPI area under the plasma concentration-time curve (AUCR) in the presence/absence of OATP1B inhibitor rifampin was higher in patients with CKD compared with healthy participants, in contrast to pitavastatin (a clinical OATP1B probe). This study investigated mechanism(s) contributing to altered CPI baseline in patients with CKD by extending a previously developed physiologically-based pharmacokinetic (PBPK) model to this patient population. CKD-related covariates were evaluated in a stepwise manner on CPI fraction unbound in plasma (fu,p ), OATP1B-mediated hepatic uptake clearance (CLactive ), renal clearance (CLR ), and endogenous synthesis (ksyn ). The CPI model successfully recovered increased baseline and rifampin-mediated AUCR in patients with CKD by accounting for the following disease-related changes: 13% increase in fu,p , 29% and 39% decrease in CLactive in mild and moderate to severe CKD, respectively, decrease in CLR proportional to decline in glomerular filtration rate, and 27% decrease in ksyn in severe CKD. Almost complete decline in CPI renal elimination in severe CKD increased its fraction transported by OATP1B, rationalizing differences in the CPI-rifampin interaction observed between healthy participants and patients with CKD. In conclusion, mechanistic modeling performed here supports CKD-related decrease in OATP1B function to inform prospective PBPK modeling of OATP1B-mediated drug-drug interaction in these patients. Monitoring of CPI allows detection of CKD-drug interaction risk for OATP1B drugs with combined hepatic and renal elimination which may be underestimated by extrapolating the interaction risk based on pitavastatin data in healthy participants.
引用
- Takita H, Scotcher D, Chu X, et al. Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease. Clin Pharmacol Ther. 2022. PMID: 35652251. doi:10.1002/cpt.2672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。